Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01)

NCT05000216 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT05000216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05000216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01)
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 2
Overall status
Terminated
Start date
August 13, 2021
Completion date
March 28, 2024
Enrollment
258 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

juvenile dermatomyositis (jdm), juvenile idiopathic arthritis (jia), multiple sclerosis (ms), pediatric sle, pediatric-onset multiple sclerosis (poms), pemphigus vulgaris, rheumatoid arthritis (ra), systemic lupus erythematosus (sle), systemic sclerosis (ssc)